In regard to these mechanisms, Nishimoto et al. analyzed the kinetics of serum IL-6 and soluble IL-6 receptor (sIL-6R) as well as the proportion of sIL-6R saturated with tocilizumab after its administration to patients with RA and Castleman disease. This evidence concerns the gene IL6R and rheumatoid arthritis.